Royalty Pharma PLCNASDAQ:RPRX
- LAST PRICE26.6600
- TODAY'S CHANGE (%)0.0600 (0.2256%)
- Bid / Lots26.5000/ 1
- Ask / Lots27.0000/ 2
- Open / Previous Close26.6000 / 26.6000
- Day Range
- 52 Week Range
- Volume1,397,441
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RPRX |
|---|---|---|
| 09:32 ET | 22714 | 26.648 |
| 09:33 ET | 1874 | 26.62 |
| 09:35 ET | 1188 | 26.64 |
| 09:37 ET | 3486 | 26.615 |
| 09:39 ET | 1549 | 26.56 |
| 09:42 ET | 2127 | 26.568539 |
| 09:44 ET | 8197 | 26.51 |
| 09:46 ET | 3966 | 26.51 |
| 09:48 ET | 3169 | 26.49 |
| 09:50 ET | 6491 | 26.51 |
| 09:51 ET | 2295 | 26.5 |
| 09:53 ET | 4500 | 26.49 |
| 09:55 ET | 2300 | 26.48 |
| 09:57 ET | 5116 | 26.5 |
| 10:00 ET | 16055 | 26.49 |
| 10:02 ET | 1907 | 26.46 |
| 10:04 ET | 1005 | 26.475 |
| 10:06 ET | 6243 | 26.54 |
| 10:08 ET | 2916 | 26.515 |
| 10:09 ET | 1015 | 26.5 |
| 10:11 ET | 2027 | 26.48 |
| 10:13 ET | 9096 | 26.49 |
| 10:15 ET | 1977 | 26.485 |
| 10:18 ET | 7367 | 26.462764 |
| 10:20 ET | 5553 | 26.46 |
| 10:22 ET | 7011 | 26.505 |
| 10:24 ET | 1011 | 26.505 |
| 10:26 ET | 10430 | 26.53 |
| 10:27 ET | 1651 | 26.52 |
| 10:29 ET | 4209 | 26.535 |
| 10:31 ET | 3375 | 26.54 |
| 10:33 ET | 1401 | 26.535 |
| 10:36 ET | 1782 | 26.53 |
| 10:38 ET | 2205 | 26.535 |
| 10:40 ET | 11184 | 26.475 |
| 10:42 ET | 6575 | 26.49 |
| 10:44 ET | 1336 | 26.49 |
| 10:45 ET | 2818 | 26.49 |
| 10:47 ET | 4407 | 26.475 |
| 10:49 ET | 2257 | 26.475 |
| 10:51 ET | 1540 | 26.495 |
| 10:54 ET | 2762 | 26.495 |
| 10:56 ET | 1300 | 26.495 |
| 10:58 ET | 1696 | 26.495 |
| 11:00 ET | 4347 | 26.5071 |
| 11:02 ET | 1737 | 26.515 |
| 11:03 ET | 1200 | 26.51 |
| 11:05 ET | 2426 | 26.515 |
| 11:07 ET | 6210 | 26.535 |
| 11:09 ET | 2638 | 26.535 |
| 11:12 ET | 1600 | 26.53 |
| 11:14 ET | 2662 | 26.515 |
| 11:16 ET | 2500 | 26.515 |
| 11:18 ET | 1750 | 26.515 |
| 11:20 ET | 5563 | 26.535 |
| 11:21 ET | 3521 | 26.54 |
| 11:23 ET | 4111 | 26.535 |
| 11:25 ET | 1492 | 26.535 |
| 11:27 ET | 5172 | 26.58 |
| 11:30 ET | 5324 | 26.625 |
| 11:32 ET | 1144 | 26.625 |
| 11:34 ET | 7038 | 26.625 |
| 11:36 ET | 2307 | 26.625 |
| 11:38 ET | 7587 | 26.625 |
| 11:39 ET | 2481 | 26.62 |
| 11:41 ET | 1469 | 26.615 |
| 11:43 ET | 1031 | 26.61 |
| 11:45 ET | 5493 | 26.595 |
| 11:48 ET | 2038 | 26.595 |
| 11:50 ET | 2372 | 26.57 |
| 11:52 ET | 4459 | 26.57 |
| 11:54 ET | 2378 | 26.545 |
| 11:56 ET | 16357 | 26.55 |
| 11:57 ET | 2210 | 26.575 |
| 11:59 ET | 2758 | 26.55 |
| 12:01 ET | 3509 | 26.535 |
| 12:03 ET | 1762 | 26.54 |
| 12:06 ET | 5779 | 26.58 |
| 12:08 ET | 2039 | 26.575 |
| 12:10 ET | 1500 | 26.575 |
| 12:12 ET | 600 | 26.575 |
| 12:14 ET | 3784 | 26.56 |
| 12:15 ET | 1874 | 26.57 |
| 12:17 ET | 1278 | 26.57 |
| 12:19 ET | 6772 | 26.57 |
| 12:21 ET | 4826 | 26.575 |
| 12:24 ET | 7082 | 26.59 |
| 12:26 ET | 4180 | 26.565 |
| 12:28 ET | 2300 | 26.565 |
| 12:30 ET | 3400 | 26.56 |
| 12:32 ET | 2924 | 26.56 |
| 12:33 ET | 3830 | 26.545 |
| 12:35 ET | 3526 | 26.54 |
| 12:37 ET | 6897 | 26.54 |
| 12:39 ET | 5196 | 26.535 |
| 12:42 ET | 3509 | 26.525 |
| 12:44 ET | 3062 | 26.535 |
| 12:46 ET | 4447 | 26.54 |
| 12:48 ET | 1240 | 26.54 |
| 12:50 ET | 5541 | 26.54 |
| 12:51 ET | 19183 | 26.6 |
| 12:53 ET | 4474 | 26.625 |
| 12:55 ET | 15853 | 26.595 |
| 12:57 ET | 27735 | 26.6162 |
| 01:00 ET | 543638 | 26.66 |
Nov 27, 2024
Royalty Pharma to Present at Upcoming Investor Conferences, from 4:15PM ET on Wednesday Nov 27, 2024 by Dow Jones
4:15PM ET on Wednesday Nov 27, 2024 by Dow Jones
Nov 14, 2024
Royalty Pharma Announces Inaugural Prize for Impact in Healthcare, from 4:30PM ET on Thursday Nov 14, 2024 by Dow Jones
4:30PM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 7, 2024
Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million, from 7:10AM ET on Thursday Nov 07, 2024 by Dow Jones
7:10AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 6, 2024
Royalty Pharma Reports Third Quarter 2024 Results, from 7:15AM ET on Wednesday Nov 06, 2024 by Dow Jones
7:15AM ET on Wednesday Nov 06, 2024 by Dow Jones*DJ Royalty Pharma 3Q Net $544M >RPRX, from 7:15AM ET on Wednesday Nov 06, 2024 by Dow Jones
7:15AM ET on Wednesday Nov 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Royalty Pharma PLC | 15.5B | 10.4x | +1.83% |
Amneal Pharmaceuticals Inc | 2.6B | -12.1x | --- |
Catalent Inc | 11.1B | -26.9x | --- |
Endo Inc | 1.8B | 0.4x | --- |
Jazz Pharmaceuticals PLC | 7.4B | 17.1x | -3.53% |
Prestige Consumer Healthcare Inc | 4.2B | 20.7x | --- |
Company Information
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.
Contact Information
- Headquarters
- 110 East 59th StreetNEW YORK, NY, United States 10022
- Phone
- 212-883-0200
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Pablo Legorreta
- Vice Chairman, Executive Vice President
- Christopher Hite
- Chief Financial Officer, Executive Vice President
- Terrance Coyne
- Executive Vice President - Investments and Chief Legal Officer
- George Lloyd
- Executive Vice President - Head of Human Capital
- Molly Sawaya
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $15.5B |
|---|---|
Revenue (TTM) | $2.3B |
Shares Outstanding | 589.2M |
Dividend Yield | 3.15% |
Annual Dividend Rate | 0.8400 USD |
Ex-Dividend Date | 11-15-24 |
Pay Date | 12-10-24 |
Beta | 0.46 |
EPS | $2.56 |
Book Value | $14.61 |
P/E Ratio | 10.4x |
Price/Sales (TTM) | 6.8 |
Price/Cash Flow (TTM) | 21.6x |
Operating Margin | 68.13% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
